NCT00460694View on ClinicalTrials.gov

Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid LeukemiaNon Hodgkin's LymphomaHodgkin's DiseaseMyelodysplastic SyndromeMultiple Myeloma

Interventions

BIOLOGICAL

infusion of allogeneic CIK cells

infusion of allogeneic CIK cells at graded doses

Trial Locations (1)

169608

Singapore General Hospital, Singapore

All Listed Sponsors

collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

Singapore General Hospital

OTHER

NCT00460694 - Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies | Biotech Hunter | Biotech Hunter